VJOncology is committed to improving our service to you

ESMO 2020 | Update on biomarkers in urothelial cancer presented at ESMO 2020

VJOncology is committed to improving our service to you

Thomas Powles

Thomas Powles, MBBS, MCRP, Barts Cancer Institute, London, UK, gives an updated summary on biomarkers in urothelial cancer presented at ESMO 2020. Prof. Powles discusses five different biomarkers that are used for measuring PD-L1 expression. These include SP142, 22C3, tumor mutation burden (TMB), CD8 and transforming growth factor (TGF-β). Studies have suggested that positive data for the aforementioned biomarkers are yet to be confirmed within randomized, Phase III study. A key question for future study is whether the PD-L1 biomarker can be sandwiched together with other biomarkers to increase enrichment of patient immunity. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter